
Program Memorandum Carriers

Department of Health &
Human Services (DHHS)
Centers for Medicare &
Medicaid Services (CMS)

Transmittal B-02-016

Date: MARCH 22, 2002

CHANGE REQUEST 2064

SUBJECT: Addition of Four “WW” Codes to Identify a New Source for Methotrexate

Suppliers are currently instructed to bill oral anti-cancer drugs to the DMERCs using the appropriate National Drug Code (NDC). The addition of these “WW” codes will allow the DMERCs to correctly adjudicate this oral anti-cancer drug. The proposed additions would read:

WW100 - Methotrexate, 5mg, oral	(00555-0927-01)
WW101 - Methotrexate, 7.5mg, oral	(00555-0928-01)
WW102 - Methotrexate, 10mg, oral	(00555-0929-01)
WW103 - Methotrexate, 15mg, oral	(00555-0945-01)

Trexall is the brand name for the 5, 7.5, 10, and 15mg methotrexate. These strengths are not yet available in a generic form.

NOTE: WW codes are for DMERC internal systems processing only and providers should still bill using the appropriate NDC codes for oral anti-cancer drugs.

The approval date for Medicare coverage for the above drug is April 30, 2001.

(DMEPOS category:9)(CWF category:17,60)(POS: 12,31,32,33,54,55,56)(TOS:9)

The *effective date* for this Program Memorandum (PM) is July 1, 2002.

The *implementation date* for this PM is July 1, 2002.

These instructions should be implemented within your current operating budget.

This PM may be discarded after July 1, 2003.

If you have any questions, contact Angie Costello at (410)786-1554 or acostello@cms.hhs.gov.